Along the lines of Buzz’s comment, I would like to see STAT be more careful about attacking small biotech companies. There are certain other STAT authors who are somewhat infamous for this habit (not this author). These small companies are often trying new approaches and they don’t need extra criticism for it to scare away investors. The seed for the next Alzheimer’s drug may very well originate from a small biotech that is easy to criticize in the early stages.
Also in Industry News
A comprehensive analysis of evidence-based information to help manage myopia - News-Medical.Net
Applying AI to map how COVID-19 virus attacks the heart
Abnormal calcium levels in mitochondria may cause neuronal cell death in Alzheimer's disease